HRP20150932T2 - Heterociklički spojevi - Google Patents
Heterociklički spojevi Download PDFInfo
- Publication number
- HRP20150932T2 HRP20150932T2 HRP20150932TT HRP20150932T HRP20150932T2 HR P20150932 T2 HRP20150932 T2 HR P20150932T2 HR P20150932T T HRP20150932T T HR P20150932TT HR P20150932 T HRP20150932 T HR P20150932T HR P20150932 T2 HRP20150932 T2 HR P20150932T2
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- alkylene
- attached
- compound
- heterocycloalkyl
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 17
- 125000002947 alkylene group Chemical group 0.000 claims 12
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 3
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- 229910003827 NRaRb Inorganic materials 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 206010055665 Corneal neovascularisation Diseases 0.000 claims 1
- 208000012239 Developmental disease Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010061172 Gastrointestinal injury Diseases 0.000 claims 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- 208000013875 Heart injury Diseases 0.000 claims 1
- 206010065630 Iris neovascularisation Diseases 0.000 claims 1
- 206010067125 Liver injury Diseases 0.000 claims 1
- 208000004852 Lung Injury Diseases 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- 208000029549 Muscle injury Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 206010033627 Pancreatic injury Diseases 0.000 claims 1
- 206010061481 Renal injury Diseases 0.000 claims 1
- 206010038934 Retinopathy proliferative Diseases 0.000 claims 1
- 208000028990 Skin injury Diseases 0.000 claims 1
- 206010069363 Traumatic lung injury Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000000159 corneal neovascularization Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 229940012356 eye drops Drugs 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 231100000753 hepatic injury Toxicity 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000037806 kidney injury Diseases 0.000 claims 1
- 201000002818 limb ischemia Diseases 0.000 claims 1
- 231100000515 lung injury Toxicity 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 210000002027 skeletal muscle Anatomy 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 231100000827 tissue damage Toxicity 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/54—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (12)
1. Spoj prema slijedećoj formuli:
[image]
naznačen time da
svaki Q i U je CH ili N, pod uvjetom da barem jedan od Q i U je N;
svaki X, Y, i Z, neovisno, je C1-5 alkilen ili izbrisan;
m je 0, 1, 2, 3, 4, ili 5;
n je 0, 1 ili 2;
p je 1 ili 2;
R1 je H, C1-C10 alkil, C3-C20 cikloalkil, C1-C20 heterocikloalkil, aril, heteroaril, halo, CN, ORa, COORa, OC(O)Ra, C(O)Ra, C(O)NRaRb, ili NRaRb;
R2 je C1-C10 alkil, C3-C20 cikloalkil, C1-C20 heterocikloalkil, aril, heteroaril, ili C1-C10 alkil, proizvoljno supstituiran s C1-C10 alkil, C3-C20 cikloalkil, C1-C20 heterocikloalkil, ili N(RCRd);
R3, neovisno, je C1-C10 alkil, C3-C20 cikloalkil, C1-C20 heterocikloalkil, aril, heteroaril, halo, CN, ORe, COORe, OC(O)Re, C(O)Re, C(O)NReRf, ili NReRf; ili R3 je C1-5 alkilen vezan na dva ugljikova atoma prstena na koji je vezan ili C2-8 alkilen vezan na jedan ugljikov atom prstena na koji je vezan; i
R4 je P(=O)(ORg)(ORi), P(=O)(NHRg)(ORi), P(=O)(NRg)(NRi);
gdje svaki od Ra, Rb, RC, Rd, Re, Rf, Rg i Ri, neovisno, je H, C1-C10 alkil, C3-C20 cikloalkil, C1-C20 heterocikloalkil, aril, heteroaril, ili -C(O)R, R je H, C1-C10 alkil, C3-C20 cikloalkil, C1-C20 heterocikloalkil, aril, ili heteroaril; ili Ra i Rb su vezani i zajedno tvore C2-8 alkilen, RC i Rd su vezani i zajedno tvore C2-8 alkilen, Re i Rf su vezani i zajedno tvore C2-8 alkilen, ili Rg i Ri su vezani i zajedno tvore C1-5 alkilen.
2. Spoj prema zahtjevu 1, naznačen time da Q je CH ili N i U je N.
3. Spoj prema zahtjevu 1, naznačen time da X je -CH2-, -CH2CH2- ili -CH2CH2CH2- i p je 1.
4. Spoj prema zahtjevu 1, naznačen time da Y je -CH2 ili izbrisan i Z je -CH2-.
5. Spoj prema zahtjevu 1, naznačen time da R2 je C1-5 alkil supstituiran s N(RCRd), poželjno -CH2CH2CH2-N(RCRd), gdje RC je H i Rd je C1-C10 alkil, C3-C20 cikloalkil, C1-C20 heterocikloalkil, aril, ili heteroaril, ili RC i Rd su vezani i zajedno tvore C4-6 alkilen.
6. Spoj prema zahtjevu 1, naznačen time da m je 0, 1, ili 2; n je 1 ili 2; R1 je NH2; i R3 je C1-C3 alkil, C3-C8 cikloalkil, C1-C8 heterocikloalkil, aril, heteroaril, halo, CN, ORe, ili C(O)NReRf; ili R3 je C1-2 alkilen vezan na dva ugljikova atoma prstena na koji je vezan ili C2-5 alkilen vezan na jedan ugljikov atom prstena na koji je vezan.
7. Spoj prema zahtjevu 1, naznačen time da R4 je P(=O)(OH)2, P(=O)(OH)(OCH2CH3), P(=O)(OCH2CH3)2,
[image]
i
pri čemu poželjno m je 0, 1, ili 2; n je 1; p je 1; X je -CH2CH2- ili -CH2CH2CH2-; Y je -CH2 ili izbrisan i Z je -CH2-; R1 je NH2; R2 je C1-5 alkil supstituiran N(RCRd); i R3 je C1-C3 alkil, C3-C8 cikloalkil, C1-C8 heterocikloalkil, aril, heteroaril, halo, CN, ORe, ili C(O)NReRf; ili C1-2 alkilen vezan na dva ugljikova atoma prstena na koji je vezan ili C2-5 alkilen vezan na jedan ugljikov atom prstena na koji je vezan.
8. Spoj prema zahtjevu 1, naznačen time da je spoj odabran iz skupine koja se sastoji od slijedećih spojeva
[image]
[image]
[image]
[image]
[image]
9. Spoj kao što je definirano u bilo kojem od zahtjeva 1 do 8, naznačen time da je za uporabu u liječenju medicinskog stanja povezanog s CXCR4, pri čemu je stanje upalna ili imunološka bolest, razvojna ili degenerativna bolest, ili oštećenje tkiva, poželjno izabrano iz skupine koja sadrži dijabetes melitus tipa I, ozljedu mozga, ozljedu živca, ozljedu srca, oštećenje jetre, ozljedu skeletnih mišića, oštećenje bubrega, oštećenje gušterače, ozljedu pluća, ozljedu kože, ishemiju udova, tihu ishemiju, srčanu ishemiju, ili ozljedu gastrointestinalnog trakta, pri čemu se spoj poželjno primjenjuje u kombinaciji s faktorom rasta G-CSF.
10. Spoj za uporabu u liječenju medicinskog stanja povezanog s CXCR4 prema zahtjevu 9, naznačen time da medicinsko stanje je dijabetička retinopatija, proliferativna retinopatija, makularna degeneracija povezna sa starenjem, makularni edem, neovaskularizacija rožnice, ili neovaskularizacija šarenice.
11. Spoj za uporabu u liječenju medicinskog stanja povezanog s CXCR4 prema zahtjevu 10, naznačen time da je spoj u pripravku formuliranom kao kapi za oči, pomast, injekcijska tekućina, mikročestice, ili oblik s produljenim otpuštanjem.
12. Spoj kao što je definirano u zahtjevima 1 do 8, za uporabu za liječenje raka, naznačen time da se spoj daje u kombinaciji s učinkovitom količinom kemoterapeutskog sredstva.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4649608P | 2008-04-21 | 2008-04-21 | |
| PCT/US2008/082202 WO2009131598A1 (en) | 2008-04-21 | 2008-11-03 | Heterocyclic compounds |
| EP08874003.0A EP2268635B1 (en) | 2008-04-21 | 2008-11-03 | Heterocyclic compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20150932T1 HRP20150932T1 (en) | 2015-10-09 |
| HRP20150932T2 true HRP20150932T2 (hr) | 2017-10-20 |
Family
ID=41201620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150932TT HRP20150932T2 (hr) | 2008-04-21 | 2015-09-07 | Heterociklički spojevi |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8372849B2 (hr) |
| EP (1) | EP2268635B1 (hr) |
| JP (1) | JP5661607B2 (hr) |
| KR (1) | KR101579999B1 (hr) |
| CN (1) | CN101565404B (hr) |
| AU (1) | AU2008355098B2 (hr) |
| CA (1) | CA2720229C (hr) |
| CY (1) | CY1116802T1 (hr) |
| DK (1) | DK2268635T3 (hr) |
| EA (1) | EA019289B1 (hr) |
| ES (1) | ES2545731T3 (hr) |
| HK (1) | HK1138269A1 (hr) |
| HR (1) | HRP20150932T2 (hr) |
| HU (1) | HUE025179T2 (hr) |
| NZ (1) | NZ588989A (hr) |
| PL (1) | PL2268635T3 (hr) |
| PT (1) | PT2268635E (hr) |
| SI (1) | SI2268635T1 (hr) |
| TW (1) | TWI444188B (hr) |
| WO (1) | WO2009131598A1 (hr) |
| ZA (1) | ZA201008262B (hr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010056847A2 (en) * | 2008-11-13 | 2010-05-20 | Taigen Biotechnology Co., Ltd. | Lyophilization formulation |
| CN103204816B (zh) | 2012-01-16 | 2016-04-27 | 中国人民解放军军事医学科学院毒物药物研究所 | 哌嗪基嘧啶类衍生物及其制备方法和用途 |
| EP2836214B1 (en) * | 2012-04-11 | 2018-06-27 | Acerta Pharma B.V. | Bruton's tyrosine kinase inhibitors for hematopoietic mobilization |
| RU2704008C2 (ru) | 2014-09-22 | 2019-10-23 | Нэшнл Хелс Ресерч Инститьютс | Гетероциклические соединения и их применение |
| US9375406B2 (en) * | 2014-09-30 | 2016-06-28 | Taigen Biotechnology Co., Ltd. | Substituted pyrimidines for mobilizing cells expressing a type 4 CXC chemokine receptor |
| TWI620748B (zh) | 2016-02-05 | 2018-04-11 | National Health Research Institutes | 氨基噻唑化合物及其用途 |
| RU2756055C2 (ru) * | 2017-01-10 | 2021-09-24 | Нэшнл Хелт Рисерч Инститьютс | Гетероциклические соединения и их применение |
| CN109553604B (zh) * | 2017-09-25 | 2021-08-27 | 盛世泰科生物医药技术(苏州)有限公司 | 4-氨基嘧啶衍生物作cxcr4抑制剂及其应用 |
| CN108794414B (zh) * | 2018-06-22 | 2021-01-01 | 浙江大学 | 芳酰胺基取代的均三嗪类化合物及制备和应用 |
| CN116120195A (zh) * | 2022-12-29 | 2023-05-16 | 长兴宜生药物科技有限公司 | 一种催化制备培哚普利中间体的方法 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3007A (en) * | 1843-03-21 | Improvement in salt-boilers | ||
| US6029A (en) * | 1849-01-16 | Method of directing the scoops in dredging machines | ||
| US5034560A (en) * | 1990-10-19 | 1991-07-23 | The Standard Oil Company | Synthesis of ethylamines |
| EP0594772B1 (en) | 1991-07-04 | 1996-08-28 | Immunodex K/S | Water-soluble, polymer-based reagents and conjugates comprising moieties derived from divinyl sulfone |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| IL112795A (en) | 1994-03-04 | 2001-01-28 | Astrazeneca Ab | Derivatives of peptides as antithrombotic drugs, their preparation, and pharmaceutical preparations containing them |
| AU7692996A (en) | 1995-12-01 | 1997-06-27 | Ciba-Geigy Ag | Receptor antagonists |
| TW440563B (en) | 1996-05-23 | 2001-06-16 | Hoffmann La Roche | Aryl pyrimidine derivatives and a pharmaceutical composition thereof |
| WO1997046250A1 (en) | 1996-06-04 | 1997-12-11 | Synaptic Pharmaceutical Corporation | Methods of modifying feeding behavior, compounds useful in such methods, and dna encoding a hypothalamic atypical neuropeptide y/peptide yy receptor (y5) |
| NO311614B1 (no) * | 1996-10-01 | 2001-12-17 | Janssen Pharmaceutica Nv | Substituerte diamino-1,3,5-triazinderivater |
| AR038955A1 (es) * | 1996-12-05 | 2005-02-02 | Amgen Inc | Compuestos de pirimidinona y piridona sustituidos y metodos para su uso |
| JP2003504301A (ja) | 1998-04-01 | 2003-02-04 | ブリストル−マイヤーズ スクイブ ファーマ カンパニー | インテグリンアンタゴニスト |
| US6420354B1 (en) * | 1998-06-08 | 2002-07-16 | Advanced Medicine, Inc. | Sodium channel drugs and uses |
| BR9913374A (pt) | 1998-08-20 | 2001-05-15 | Agouron Pharmaceticals Inc | Compostos de gnrh não peptìdicos, composição farmacêutica e métodos para regular a secreção de gonadotropinas em mamìferos |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| US6274588B1 (en) | 1999-05-31 | 2001-08-14 | Hoffmann-La Roche Inc. | 4-phenyl-pyrimidine derivatives |
| JP2003519143A (ja) * | 1999-12-28 | 2003-06-17 | ファーマコピーア，インコーポレーティッド | ピリミジン及びトリアジン系キナーゼ阻害剤 |
| US6664247B2 (en) | 2000-12-21 | 2003-12-16 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| WO2003024448A2 (en) * | 2001-09-14 | 2003-03-27 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| US6897220B2 (en) | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| WO2003026666A1 (en) | 2001-09-26 | 2003-04-03 | Bayer Pharmaceuticals Corporation | 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors |
| CA2460594A1 (en) | 2001-10-01 | 2003-04-10 | Taisho Pharmaceutical Co., Ltd. | Mch receptor antagonists |
| MXPA04012855A (es) | 2002-06-28 | 2005-04-19 | Yamanouchi Pharma Co Ltd | Derivado de diaminopirimidincarboxiamida. |
| AU2003288994A1 (en) * | 2002-12-10 | 2004-06-30 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic compounds and medicinal use thereof |
| DE602004022633D1 (de) | 2003-01-30 | 2009-10-01 | Boehringer Ingelheim Pharma | 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen |
| KR100806603B1 (ko) | 2003-09-22 | 2008-02-29 | 에프. 호프만-라 로슈 아게 | 아미노알킬아미드 치환된 사이클로헥실 유도체 |
| KR101258504B1 (ko) * | 2004-03-26 | 2013-04-26 | 메틸진 인코포레이티드 | 히스톤 데아세틸라제의 억제제 |
| EP1751115A4 (en) | 2004-05-23 | 2010-10-20 | Gerard M Housey | THERAMUTEINMODULATOREN |
| JP2006124387A (ja) * | 2004-09-30 | 2006-05-18 | Taisho Pharmaceut Co Ltd | 新規なキノリン、テトラヒドロキナゾリン、及びピリミジン誘導体と、これらを使用することに関連した治療方法 |
| US20060281712A1 (en) * | 2005-06-14 | 2006-12-14 | Chi-Feng Yen | Pyrimidine compounds |
| NZ566744A (en) | 2005-08-29 | 2011-04-29 | Gerard M Housey | Theramutein modulators |
| ES2378153T3 (es) | 2005-09-27 | 2012-04-09 | Irm Llc | Conpuestos y composiciones que contienen diarilamina, y su uso como moduladores de receptores c-kit |
| CA2631182C (en) | 2005-11-23 | 2019-08-06 | Gerard M. Housey | Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators |
| JP2009530288A (ja) | 2006-03-16 | 2009-08-27 | ノバルティス アクチエンゲゼルシャフト | 特に黒色腫の処置のためのヘテロ環式有機化合物 |
| WO2007129195A2 (en) | 2006-05-04 | 2007-11-15 | Pfizer Products Inc. | 4-pyrimidine-5-amino-pyrazole compounds |
| AU2007269540B2 (en) * | 2006-07-05 | 2013-06-27 | Exelixis, Inc. | Methods of using IGF1R and Abl kinase modulators |
-
2008
- 2008-11-03 NZ NZ588989A patent/NZ588989A/en unknown
- 2008-11-03 CA CA2720229A patent/CA2720229C/en active Active
- 2008-11-03 EA EA201071221A patent/EA019289B1/ru unknown
- 2008-11-03 JP JP2011504995A patent/JP5661607B2/ja active Active
- 2008-11-03 AU AU2008355098A patent/AU2008355098B2/en active Active
- 2008-11-03 US US12/263,671 patent/US8372849B2/en active Active
- 2008-11-03 DK DK08874003.0T patent/DK2268635T3/en active
- 2008-11-03 ES ES08874003.0T patent/ES2545731T3/es active Active
- 2008-11-03 PL PL08874003T patent/PL2268635T3/pl unknown
- 2008-11-03 KR KR1020107025309A patent/KR101579999B1/ko active IP Right Grant
- 2008-11-03 PT PT88740030T patent/PT2268635E/pt unknown
- 2008-11-03 HU HUE08874003A patent/HUE025179T2/en unknown
- 2008-11-03 SI SI200831498T patent/SI2268635T1/sl unknown
- 2008-11-03 WO PCT/US2008/082202 patent/WO2009131598A1/en active Application Filing
- 2008-11-03 EP EP08874003.0A patent/EP2268635B1/en active Active
- 2008-11-05 TW TW097142682A patent/TWI444188B/zh active
- 2008-12-01 CN CN2008101796944A patent/CN101565404B/zh active Active
-
2010
- 2010-04-26 HK HK10104050.7A patent/HK1138269A1/xx unknown
- 2010-11-18 ZA ZA2010/08262A patent/ZA201008262B/en unknown
-
2015
- 2015-09-07 HR HRP20150932TT patent/HRP20150932T2/hr unknown
- 2015-09-07 CY CY20151100774T patent/CY1116802T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK2268635T3 (en) | 2015-09-14 |
| HK1138269A1 (en) | 2010-08-20 |
| NZ588989A (en) | 2012-03-30 |
| JP2011519360A (ja) | 2011-07-07 |
| ZA201008262B (en) | 2011-07-27 |
| CA2720229A1 (en) | 2009-10-29 |
| EP2268635B1 (en) | 2015-06-10 |
| PL2268635T3 (pl) | 2015-11-30 |
| SI2268635T1 (sl) | 2015-10-30 |
| US8372849B2 (en) | 2013-02-12 |
| CN101565404B (zh) | 2012-12-05 |
| EP2268635A1 (en) | 2011-01-05 |
| PT2268635E (pt) | 2015-10-06 |
| TW200944206A (en) | 2009-11-01 |
| AU2008355098B2 (en) | 2012-11-15 |
| HUE025179T2 (en) | 2016-02-29 |
| AU2008355098A1 (en) | 2009-10-29 |
| HRP20150932T1 (en) | 2015-10-09 |
| EA201071221A1 (ru) | 2011-08-30 |
| KR20110008085A (ko) | 2011-01-25 |
| TWI444188B (zh) | 2014-07-11 |
| US20090264339A1 (en) | 2009-10-22 |
| EP2268635A4 (en) | 2012-02-22 |
| ES2545731T3 (es) | 2015-09-15 |
| CY1116802T1 (el) | 2017-03-15 |
| JP5661607B2 (ja) | 2015-01-28 |
| WO2009131598A1 (en) | 2009-10-29 |
| EA019289B1 (ru) | 2014-02-28 |
| CN101565404A (zh) | 2009-10-28 |
| CA2720229C (en) | 2015-02-17 |
| KR101579999B1 (ko) | 2015-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150932T2 (hr) | Heterociklički spojevi | |
| JP2011519360A5 (hr) | ||
| PE20130242A1 (es) | Derivados de isoxazolo-piridina | |
| JP2013502430A5 (hr) | ||
| IL263314A (en) | Use of Formula 2 receptor agonists for the treatment of ocular inflammatory diseases | |
| HRP20141169T1 (hr) | Makrocikliäśki inhibitori serin proteaze hepatitisa c | |
| PE20140408A1 (es) | Derivados espiro-oxindol como antagonistas de mdm2 | |
| HRP20171565T1 (hr) | C17-heteroaril derivati oleanolne kiseline i postupci njihove uporabe | |
| JP2009532486A5 (hr) | ||
| JP2009535307A5 (hr) | ||
| WO2008009078A3 (en) | 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | |
| CL2008003120A1 (es) | Compuestos derivados de fenilalquil-, fenilalquenil-, fenilalquinil- amina, feniltioalquilamina, fenilaminoalquilamina, fenilalcoxiamina y fenilalquilguanidina; composicion farmaceutica; y uso de los compuestos para tratar un trastorno o enfermedad oftalmologica tal como retinopatia, maculopatia, retinitis pigmentosa, uveitis, entre otras. | |
| JP2011520792A5 (hr) | ||
| JP2013500314A5 (hr) | ||
| JP2020507589A5 (hr) | ||
| JP2017505314A5 (hr) | ||
| HRP20130041T1 (hr) | Terapijska sredstva | |
| PE20080409A1 (es) | Compuestos que modulan en el receptor cb2 | |
| RU2015120478A (ru) | Пери-карбинолы | |
| PE20090435A1 (es) | Inhibidores de tetrahidropiranocromeno de gamma secretasa | |
| JP2016503797A5 (hr) | ||
| JP2015508092A5 (hr) | ||
| AR073844A1 (es) | Acido l-glutamico y derivado l-glutamina (iii) uso de los mismos y metodo para obtenerlos , composiciones farmaceuticas y métodos de diagnostico de enfermedades | |
| JP2013536833A5 (hr) | ||
| EA201070018A1 (ru) | Замещенные 2-[2-(фенил)этиламино] алканамидные производные и применение указанных соединений в качестве модуляторов натриевых и/или кальциевых каналов |